Abstract
Alzheimer’s disease (AD) is the most common cause of dementia that leads over time to profound disability. Current pharmacological interventions for AD are limited to three cholinesterase inhibitors (donepezil, rivastigmine and galantamine) and the N-Methyl-D-Aspartate (NMDA)-receptor antagonist memantine, both of which provide modest impact on cognitive and functional outcomes. In this study we aimed to evaluate the effect of current treatment for Alzheimer’s disease in different stages of dementia. Cholinesterase inhibitors alone, or in combination with memantine may be beneficial in Alzheimer’s disease depending on stage of AD. There is evidence for stabilization of cognitive function in AD for 2–5 months after the initiation of anti-dementia drugs and the efficacy over time is not fully understand.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
